Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer

Acta Oncologica

Volumn 47, Issue 6, 2008, Pages 1054-1061

  Astrup Jensen, Søren ^a   Vainer, Ben ^a   Janet Witton, Caroline ^b   Trøst Jørgensen, Jan ^b   Benn Sørensen, Jens ^a  

^a Rigshospitalet   (Denmark)

^b Dako   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLINATE CALCIUM; PEPTIDE NUCLEIC ACID; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CHROMOSOME ABERRATION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CONTROL; GENE LOSS; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; VASCULAR TUMOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 51149121463     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860801942158     Document Type: Article

References (25)

1. Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003;9:3700-4.
2. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-43.
3. Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2007;120:694-701.
4. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-6.
5. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, et al. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 2005;11:3025-31.
6. Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003;89:1486-92.
7. Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 2001;21:2149-53.
8. Scanlon KJ, Lu Y, Kashani-Sabet M, Ma J, Newman E. Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo. Adv Exp Med Biol 1988;244:127-35.
9. Jakobsen A, Nielsen JN, Gyldenkerne N, Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005;23:1365-9.
10. Johnson WG, Scholl TO, Spychala JR, Buyske S, Stenroos ES, Chen X. Common dihydrofolate reductase 19-base pair deletion allele: A novel risk factor for preterm delivery. Am J Clin Nutr 2005;81:664-8.
11. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 2000;97:7921-6.
12. Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004;10:433-9.
13. Nakayama Y, Inoue Y, Nagashima N, Katsuki T, Matsumoto K, Kadowaki K, et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer. Anticancer Res 2005;25:3755-61.
14. Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 2005;11:2612-9.
15. Jensen SA, Vilmar A, Sorensen JB. Adjuvant chemotherapy in elderly patients (>or =75 yr) completely resected for colon cancer stage III compared to younger patients: Toxicity and prognosis. Med Oncol 2006;23:521-31.
16. Nielsen KV, Ejlertsen BL, Poulsen TS, Mouridsen HT. Composition and methods for predicting outcome of treatment. Patent application WO2006128463 2006.
17. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-8.
18. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-7.
19. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999;17:1760-70.
20. Hasegawa S, Seike K, Koda K, Takiguchi N, Oda K, Hasegawa R, et al. Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. Oncol Rep 2005;13:621-6.
21. Jakob C, Liersch T, Meyer W, Baretton GB, Hausler P, Schwabe W, et al. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): Correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 2005;29:1304-9.
22. Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, Hausler P, et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-8.
23. Kashani-Sabet M, Lu Y, Leong L, Haedicke K, Scanlon KJ. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer 1990;26:383-90.
24. Chung YM, Park S, Park JK, Kim Y, Kang Y, Yoo YD. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000;159:95-101.
25. Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM. Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: A model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006;66:9369-73.